Back to News
Market Impact: 0.15
Cellectis S.A. Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026
Source: Nasdaq
Healthcare & BiotechTechnology & Innovation
Cellectis announced it will present preclinical data supporting .HEAL-101, an in vivo base-editing candidate targeting APOC3 for severe hypertriglyceridemia, at the European Society of Gene and Cell Therapy’s Annual Congress, held October 27–30, 2026. The article excerpt provides no data results or clinical outcomes.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
CLLS0.40
More News
- What investors need to know about Alphabet's stock-busting earnings report
- SK Hynix says the memory-chip shortage will last until 2030—and more than half its production is booked for the next two years
- Microsoft’s strong quarter backs up its stock rebound. Here's our new price target
- Google struggling to make AI Mode searches pay
- As Waymo expands overseas, it remains a niche cash-burning business
- Microsoft’s cloud growth accelerates, and so too does the spending